2-{2-[2-(2-[pyrid-2-yl]disulfanyl-ethoxy)ethoxy]ethyl-disulfanyl}pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-{2-[2-(2-[pyrid-2-yl]disulfanyl-ethoxy)ethoxy]ethyl-disulfanyl}pyridine
• 英文别名: 2-[2-[2-[2-(Pyridin-2-yldisulfanyl)ethoxy]ethoxy]ethyldisulfanyl]pyridine
• 化学式: C₁₆H₂₀N₂O₂S₄
• 分子量: 400.611
• InChiKey: UKDAYMFWALWQMG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  24
• 可旋转键数：
  13
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  145
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2,2'-二硫二吡啶 、 2,2'-(1,2-乙二基双氧代)双乙硫醇 在 N,N-二异丙基乙胺 作用下， 以 甲醇 为溶剂， 反应 1.5h， 以49%的产率得到2-{2-[2-(2-[pyrid-2-yl]disulfanyl-ethoxy)ethoxy]ethyl-disulfanyl}pyridine
  参考文献：
  名称：

  HYDROXYALKYL STARCH DERIVATIVES AS REACTANTS FOR COUPLING TO THIOL GROUPS

  摘要：

  本发明涉及一种羟基烷基淀粉（HAS）衍生物，其化学式为（I），其中F1是包含基团—NR′—的功能基团，其中R′为H或烷基；L是桥接F1和S的间隔物；其中HAS′是HAS分子的剩余部分，Rband Rcare —[(CR1R2)mO]n—H，且彼此相同或不同；Ra是—[(CR1R2)mO]n—H，其中HAS′是羟基烷基淀粉分子的剩余部分，或者Ra是HAS″，其中HAS′和HAS″一起是羟基烷基淀粉分子的剩余部分；R1和R2独立地是氢或具有1至4个碳原子的烷基基团，m为2至4，其中在m个CR1R2基团中，R1和R2彼此相同或不同；n为0至6。

  公开号：

  US20160311934A1

文献信息

• STABILIZED POLYMERIC THIOL REAGENTS
  申请人：Kozlowski Antoni

  公开号：US20120258985A1

  公开（公告）日：2012-10-11

  Disclosed are water soluble polymeric conjugates comprising the structure POLY-[Y—S—S-A] x , where POLY is a water soluble polymer; Y is a hydrocarbon-based spacer group, x is 1 to 25, S—S is a disulfide group attached to an sp 3 hybridized carbon of Y; and A is a covalently linked residue of a pharmacologically active molecule. Preferably, the water soluble polymer is a PEG polymer. Also disclosed are polymeric reagents useful to prepare such conjugates, and methods of their formation and use.

  本发明揭示了一种水溶性聚合物共轭物，其包括结构POLY-[Y—S—S-A]x，其中POLY是一种水溶性聚合物；Y是一个碳氢基的间隔基团，x为1至25，S—S是连接到Y的sp3杂化碳的二硫键基团；而A是一种药理活性分子的共价连接残基。最好的情况下，水溶性聚合物是一种PEG聚合物。本发明还揭示了制备这种共轭物有用的聚合物试剂，以及其形成和使用的方法。
• Stabilized Polymeric Thiol Reagents
  申请人：Kozlowski Antoni

  公开号：US20110112277A1

  公开（公告）日：2011-05-12

  Disclosed are water soluble polymeric reagents comprising the structure POLY-[Y—S—W] x , where POLY is a water soluble polymer; Y is a hydrocarbon-based spacer group, x is 1 to 25, and S—W is a thiol, protected thiol, or thiol-reactive derivative. Preferably, the water soluble polymer is a PEG polymer. Also disclosed are conjugates of such polymeric reagents with pharmaceutically relevant molecules, and methods of their formation and use.

  本发明涉及一种水溶性聚合物试剂，其包括结构POLY-[Y—S—W]x，其中POLY是一种水溶性聚合物；Y是一个碳氢基间隔基，x为1至25，S—W是一个硫醇，受保护的硫醇或硫醇反应衍生物。优选，该水溶性聚合物为PEG聚合物。本发明还涉及这种聚合物试剂与药物相关分子的结合物，以及它们的形成和使用方法。
• Muteins of clotting factor VIII
  申请人：Pfizer Inc.

  公开号：US10570189B2

  公开（公告）日：2020-02-25

  The present disclosure provides muteins of FVIII to which a biocompatible polymer may be attached to increase the circulatory half-life of the muteins, as well as conjugates of such muteins and biocompatible polymers.

  本公开提供了可附着生物相容性聚合物以延长静音素循环半衰期的 FVIII 静音素，以及此类静音素和生物相容性聚合物的共轭物。
• IMPROVED MUTEINS OF CLOTTING FACTOR VIII
  申请人：Pfizer Inc.

  公开号：EP3114138B1

  公开（公告）日：2021-11-17
• INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES
  申请人：Kannan Rangaramanujam M.

  公开号：US20130136697A1

  公开（公告）日：2013-05-30

  The invention discloses injectable hydrogels which are in the form of crosslinked nano beads or particle in the size range 5 nm to 10 μm, comprising PAMAM dendrimer with asymmetrical peripheral end groups such that one of the terminal groups is involved in formation of hydrogel and the other in involved in the conjugation of drugs or imaging agents and their methods of preparation. The said gel is formed by reaction of the PAMAM dendrimer with asymmetrical end groups with other polymer wherein the other polymer is selected from the group of linear, branched, hyperbranched or star shaped polymers with functionalized terminal groups. The PAMAM dendrimer with asymmetrical terminal groups consists of a Generation 2 and above PAMAM dendrimer with symmetrical end groups modified using the amino acids or their modified forms. The gel disclosed in the present invention is formed as small crosslinked particles in the size range 25 nm to 10 μm and is suitable for injectable delivery of hydrogel to any of the body orifices, tissues by intramuscular or subcutaneous route and ocular delivery for the purpose of therapeutic treatment and imaging.